CLIMB BIO, INC. - Common Stock, par value $0.0001 per share (CLYM) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2021 to Q3 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
CLYM on Nasdaq
Shares outstanding
54,403,891
Price per share
$2.01
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
44,576,107
Total reported value
$89,598,934
% of total 13F portfolios
0%
Share change
-5,312,025
Value change
-$10,311,691
Number of holders
66
Price from insider filings
$2.01
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of CLIMB BIO, INC. - Common Stock, par value $0.0001 per share (CLYM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RA CAPITAL MANAGEMENT, L.P. 33% $36,086,101 17,953,284 RA Capital Management, L.P. 11 Dec 2025
Pontifax Management 4 G.P. (2015) Ltd. 7.7% $12,911,822 5,206,380 Pontifax VI G.P. L.P. 27 Jun 2024

As of 30 Sep 2025, 66 institutional investors reported holding 44,576,107 shares of CLIMB BIO, INC. - Common Stock, par value $0.0001 per share (CLYM). This represents 82% of the company’s total 54,403,891 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of CLIMB BIO, INC. - Common Stock, par value $0.0001 per share (CLYM) together control 80% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RA CAPITAL MANAGEMENT, L.P. 58% 31,419,267 0% 0.78% $63,152,727
VANGUARD GROUP INC 2.4% 1,315,811 -1.2% 0% $2,644,780
Affinity Asset Advisors, LLC 2.4% 1,300,000 -13% 0.24% $2,613,000
Kynam Capital Management, LP 1.9% 1,028,341 0% 0.15% $2,066,965
TANG CAPITAL MANAGEMENT LLC 1.8% 1,000,000 0% 0.08% $2,010,000
BlackRock, Inc. 1.4% 735,503 -16% 0% $1,478,360
Peapod Lane Capital LLC 1% 561,866 +1.1% 1% $1,129,059
CANTOR FITZGERALD, L. P. 1% 547,173 -78% 0.02% $1,099,818
RENAISSANCE TECHNOLOGIES LLC 0.99% 537,100 +8.4% 0% $1,079,571
PRICE T ROWE ASSOCIATES INC /MD/ 0.97% 526,917 -3.8% 0% $1,060,000
Deep Track Capital, LP 0.94% 509,789 -51% 0.03% $1,024,676
Alyeska Investment Group, L.P. 0.89% 485,364 0% 0% $975,582
MILLENNIUM MANAGEMENT LLC 0.87% 471,704 -1.7% 0% $948,125
NAN FUNG TRINITY (HK) LTD 0.85% 463,654 0% 0.09% $931,945
SPHERA FUNDS MANAGEMENT LTD. 0.8% 434,837 +107% 0.21% $874,022
UBS Group AG 0.75% 405,404 +6% 0% $814,862
CITIGROUP INC 0.61% 329,548 -80% 0% $662,392
GEODE CAPITAL MANAGEMENT, LLC 0.57% 311,721 0% 0% $626,870
MARSHALL WACE, LLP 0.42% 229,889 +526% 0% $462,077
Shay Capital LLC 0.28% 150,000 -64% 0.05% $301,500
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.26% 142,450 +128% 0% $286,325
DIADEMA PARTNERS LP 0.25% 136,488 -81% 0.19% $274,341
ADAR1 Capital Management, LLC 0.25% 133,530 +12% 0.03% $268,395
NORTHERN TRUST CORP 0.23% 125,423 -11% 0% $252,100
TWO SIGMA INVESTMENTS, LP 0.21% 112,681 -37% 0% $226,489

Institutional Holders of CLIMB BIO, INC. - Common Stock, par value $0.0001 per share (CLYM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q3 44,576,107 $89,598,934 -$10,311,691 $2.01 66
2025 Q2 49,893,947 $61,871,600 -$2,503,053 $1.24 68
2025 Q1 51,939,064 $63,368,459 -$8,741,675 $1.22 76
2024 Q4 55,704,708 $100,269,759 -$19,354,243 $1.80 77
2024 Q3 54,655,767 $278,130,064 +$14,600,374 $5.09 69
2024 Q2 49,901,732 $354,802,230 +$245,139,552 $7.11 46
2024 Q1 16,843,283 $46,149,398 +$5,261 $2.74 19
2023 Q4 16,853,724 $45,505,627 +$348,407 $2.70 22
2023 Q3 16,728,590 $43,997,383 -$6,830 $2.63 22
2023 Q2 16,730,361 $46,844,345 +$79,299 $2.80 21
2023 Q1 16,702,070 $48,434,001 +$194,588 $2.90 19
2022 Q4 16,628,134 $61,000,699 -$1,790 $3.67 20
2022 Q3 14,807,225 $47,821,510 -$981,140 $3.23 20
2022 Q2 15,120,922 $45,670,000 -$21,550,941 $3.02 21
2022 Q1 17,488,772 $146,733,000 +$663,192 $8.39 40
2021 Q4 17,363,015 $181,615,000 +$167,770 $10.46 33
2021 Q3 17,279,143 $310,678,000 +$310,678,285 $17.98 32